You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
壽康集團(00575.HK)擬明年第二季末前就Senstend提交新藥申請
阿思達克 07-05 08:41
壽康集團(00575.HK)公布,合作夥伴江蘇萬邦醫藥於2021年12月於藥物評價中心註冊的三項藥物試驗中,兩項第一期研究已成功完成,剩下的第三期研究仍在進行中。 公司、其監管顧問及江蘇萬邦醫藥已開展籌備階段,向國家藥品監督管理局就Senstend提交新藥申請,旨在於2023年第二季末前提交新藥申請。倘臨床研究達致其終點及國家藥品監督管理局已授予Senstend進口許可證,則江蘇萬邦醫藥將須向集團支付500萬美元。此外,Senstend於中國進行首次商業銷售後,江蘇萬邦醫藥將須向集團支付200萬美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account